MannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza® in Youth with Newly-Diagnosed T1D

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/23/2026

1. GOOGL
2. TSLA
3. TXN
4. NOW
5. AMD
6. GOOG
7. INTC
8. CSX
9. IBM
10. KNX

Go back to MannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza® in Youth with Newly-Diagnosed T1D
Mannkind Corporation (NASDAQ: MNKD) Delayed: 3.89 +0.05 (1.30%)
Previous Close $3.84    52 Week High $2.51 
Open $3.73    52 Week Low $0.41 
Day High $3.91    P/E N/A 
Day Low $3.71    EPS $-0.64 
Volume 2,935,889       

Mannkind Corporation (NASDAQ: MNKD) Delayed: 3.89 +0.05 (1.30%)
Previous Close $3.84    52 Week High $2.51 
Open $3.73    52 Week Low $0.41 
Day High $3.91    P/E N/A 
Day Low $3.71    EPS $-0.64 
Volume 2,935,889